Company profile for Alaunos Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large canc...
Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical need.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
8030 El Rio St Houston, TX 77054
Telephone
Telephone
(212) 698-8802
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/06/23/3103328/18421/en/Alaunos-Therapeutics-Announces-2-0-Million-Registered-Direct-Offering.html

GLOBENEWSWIRE
23 Jun 2025

https://www.fiercebiotech.com/biotech/after-axing-its-sole-clinical-prospect-last-year-alaunos-cuts-ties-precigen

FIERCE BIOTECH
11 Oct 2024

https://www.globenewswire.com//news-release/2023/11/14/2779968/18421/en/Alaunos-Therapeutics-Announces-Third-Quarter-2023-Financial-Results-Phase-1-Clinical-Data-and-Continued-Exploration-of-Strategic-Alternatives.html

GLOBENEWSWIRE
14 Nov 2023

https://www.fiercebiotech.com/biotech/houston-biotech-winds-down-sole-clinical-stage-trial-cuts-60-its-staff

Max Bayer FIERCE BIOTECH
16 Aug 2023

https://www.globenewswire.com/news-release/2023/08/14/2725008/18421/en/Alaunos-Therapeutics-Announces-Second-Quarter-2023-Financial-Results-Interim-Clinical-Data-and-Exploration-of-Strategic-Alternatives.html

GLOBENEWSWIRE
14 Aug 2023

https://www.globenewswire.com/news-release/2023/06/29/2696871/18421/en/Alaunos-Therapeutics-Announces-Presentation-at-the-2nd-Hawaii-Global-Summit-on-Thoracic-Malignancies.html

GLOBENEWSWIRE
29 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty